<?xml version="1.0" encoding="UTF-8"?>
<p>Despite these promising results, a Chinese clinical trial (ChiC-TR2000029308) in patients with SARS-CoV-2 infection showed that treatment with lopinavirâ€“ritonavir added to standard supportive care was not associated with a statistically significant difference over standard care alone in the time to clinical improvement or mortality (
 <xref rid="B87" ref-type="bibr">87</xref>).
</p>
